Home > Research > Publications & Outputs > Surface-modified polymeric nanoparticles for dr...

Associated organisational unit


Text available via DOI:

View graph of relations

Surface-modified polymeric nanoparticles for drug delivery to cancer cells

Research output: Contribution to Journal/MagazineJournal articlepeer-review

  • A. Ahmed
  • S. Sarwar
  • Y. Hu
  • M.U. Munir
  • M.F. Nisar
  • F. Ikram
  • A. Asif
  • S.U. Rahman
  • A.A. Chaudhry
  • I.U. Rehman
<mark>Journal publication date</mark>31/01/2021
<mark>Journal</mark>Expert Opinion on Drug Delivery
Issue number1
Number of pages24
Pages (from-to)1-24
Publication StatusPublished
Early online date29/09/20
<mark>Original language</mark>English


Introduction: The utilization of polymeric nanoparticles, as drug payloads, has been extensively prevailed in cancer therapy. However, the precise distribution of these nanocarriers is restrained by various physiological and cellular obstacles. Nanoparticles must avoid nonspecific interactions with healthy cells and in vivo compartments to circumvent these barriers. Since in vivo interactions of nanoparticles are mainly dependent on surface properties of nanoparticles, efficient control on surface constituents is necessary for the determination of nanoparticles’ fate in the body. Areas covered: In this review, the surface-modified polymeric nanoparticles and their utilization in cancer treatment were elaborated. First, the interaction of nanoparticles with numerous in vivo barriers was highlighted. Second, different strategies to overcome these obstacles were described. Third, some inspiring examples of surface-modified nanoparticles were presented. Later, fabrication and characterization methods of surface-modified nanoparticles were discussed. Finally, the applications of these nanoparticles in different routes of treatments were explored. Expert opinion: Surface modification of anticancer drug-loaded polymeric nanoparticles can enhance the efficacy, selective targeting, and biodistribution of the anticancer drug at the tumor site.